QEEG ALPHA1 CHANGES AFTER A SINGLE-DOSE OF HIGH-POTENCY NEUROLEPTICS AS A PREDICTOR OF SHORT-TERM RESPONSE TO TREATMENT IN SCHIZOPHRENIC-PATIENTS

被引:36
作者
GALDERISI, S
MAJ, M
MUCCI, A
BUCCI, P
KEMALI, D
机构
[1] Department of Psychiatry, Medical School, Second University of Naples, Naples
关键词
QEEG; NEUROLEPTICS; TEST DOSE; SCHIZOPHRENIA; PREDICTION OF RESPONSE;
D O I
10.1016/0006-3223(94)90002-7
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Baseline quantitative electroencephalographic (QEEG) characteristics and their changes after a single test dose of either haloperidol or clopenthixol were investigated in a group of 29 schizophrenics as possible predictors of short-term response to those drugs. On baseline QEEG assessment, responders (R) to subsequent treatment showed fewer slow and more fast activities than nonresponders (NR). A large overlap between R and NR with respect to these measures was observed, however, revealing their practical inadequacy to predict short-term response in individual patients. On the contrary, changes in alpha1, observed 6 hr after the administration of a single test dose of either haloperidol or clopenthixol, discriminated to a very large extent between R and NR, correctly identifying 17 out of 18 R and 8 out of 10 NR. The QEEG test dose procedure might be used in the selection of the most appropriate antipsychotic drug for individual schizophrenic patients.
引用
收藏
页码:367 / 374
页数:8
相关论文
共 24 条
[1]  
ABT K, 1988, STAT TOPOGRAPHY QUAN, P150
[2]  
Andreasen N. C, 1981, SCALE ASSESSMENT NEG
[3]  
ANDREASEN NC, 1982, ARCH GEN PSYCHIAT, V39, P789
[4]  
ANDREASENNC, 1984, SCALE ASSESSMENT POS
[5]  
ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5
[6]   THE 2-SYNDROME CONCEPT - ORIGINS AND CURRENT STATUS [J].
CROW, TJ .
SCHIZOPHRENIA BULLETIN, 1985, 11 (03) :471-486
[7]   MOLECULAR PATHOLOGY OF SCHIZOPHRENIA - MORE THAN ONE DISEASE PROCESS [J].
CROW, TJ .
BRITISH MEDICAL JOURNAL, 1980, 280 (6207) :66-68
[8]  
CSEMANSKY JG, 1985, J NERV MENT DIS, V173, P325
[9]   PRETREATMENT EEG PREDICTS SHORT-TERM RESPONSE TO HALOPERIDOL TREATMENT [J].
CZOBOR, P ;
VOLAVKA, J .
BIOLOGICAL PSYCHIATRY, 1991, 30 (09) :927-942
[10]  
Galderisi S, 1990, Eur Neuropsychopharmacol, V1, P51, DOI 10.1016/0924-977X(90)90011-X